Congratulations to Molly Altenburg MD, the 5th Reyes Prevention Fellow. I was blessed this year with her passion for patient care, enthusiasm for learning Lipidology, outstanding teaching and warm personality. Molly is graduating to lead the Prevention/Lipidology Center at Rush.

Saddened to hear the news of the passing of one of my hero's, Scott Grundy MD PhD. Scott was a pioneer in the burgeoning field of Lipidology, a influential researcher of both nutrition and pharmaceuticals, a great teacher and leader of the national cholesterol guidelines along.

My first patient to start olezarsen ( anti-apoC3 ASO). She is LPL - Heterozygous but also has two ApoA5 SNPs. She has had at least 10 episodes of pancreatitis in the past 2 years and severe eruptive xanthomas despite weekly plasmapheresis. Hoping for a new lease on life!

Excited and proud of the Obicetrapib BROOKLYN trial in patients with HeFH as a late breaker at AHA. Thanks Steve Nicholls for an awesome presentation

My Lipid Legend Podcast on Healio. I enjoy working with my longterm friend Ron Corderio.

This is the obituary in the NYT of the 117 year old women with the loss of function CETP variant identified in the Bronx Aging Study.

Before and after xanthoma regression in a patient with the Lebanese FH mutation. Interventional lipidology works much better than plastic surgery.

RT @JohnKastelein: Thank you to the hundreds of patients and investigators across ten countries who participated in our Phase 3 BROOKLYN tr….

My first patient with serial CLEERLYs following two years of Repatha. With excellent control of LDL-C and a reduction in Lp(a) there is a marked decrease in non-calcified plaque volume and an increase in calcified plaque. The patient is happy and so is his interventional

The Prevention World lost a giant. George Bakris was the most prolific researcher, teacher and clinician in the history of hypertension. He will live on through his great work. I will remember him most as a great friend and colleague who was always eager to help with his amazing

RT @NewAmsPharma: Two conferences, two continents, one growing team and one goal: To share new research on our investigational CETP inhibit….

RT @NewAmsPharma: We’re excited to kick off our R&D Day event this morning. Investors are invited to join our live webcast to learn more ab….

RT @BenjaminAbella: As a medical school professor, I spoke yesterday at a #upenn session with President, Provost and others. Here is what….

Thanks for all the feedback. Yes insulin resistance (IR) is the main driver behind LDL-c vs LDL-p discordance but also apoB vs LDL-p discordance ( see attached by the iconic Tom Dayspring)In the setting of IR, I recommend low carb diets. Keto may work but in susceptible patients.

LDL-p vs ApoB. Both outperform LDL-c and perhaps non-HDL-c in risk assessment especially on statins. Although, I am big fan of ApoB, I often prefer LDL-p because discordance from LDL-c is more evident. This is a good example in a patient with premature ASCVD on a statin.

RT @NewAmsPharma: We’ve met the enrollment target in our pivotal Phase 3 PREVAIL CVOT and, driven by strong interest globally, expect to ra….

Listen to a incredible podcast of my primary care physician brother, Elliott interviewing my son, Preventive Cardiologist David. I am a very proud brother and father.

My biotech TV interview about the history of New Amsterdam Pharma and Obicetrapib

48 yo male presents with LDL > 350mg/dl and Xanthelesmas. His "FH was cured after stopping the Carnivore diet and xanthelesmas are resolving. Now on a statin due to CAC score of 355. We need to warn people about the potential harm of the carnivore diet.